Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus FLAC.
EMFLAZA vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
Adults: 40 mg orally twice daily.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
2-4 hours; prolonged in renal impairment (up to 12 hours)
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid
Corticosteroid